Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
This usually necessitates a specific clinical trial design, which is a major cost driver but also a source of new, defensible IP
The list can go on
By Donna Monthei, RDN, LD | Originally Published: March 25, 2025 | Medically Reviewed on June 18, 2026 Introduction: Understanding the GLP-1 and Constipation Connection GLP-1 receptor agonists have revolutionized treatment for both type 2 diabetes and obesity management
Anything with calories, including protein shakes and fat-based coffees
